Clinical Trials
751 trialsSARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors
Sarcoma Alliance for Research through Collaboration
CAR-T Followed by Bispecific Antibodies
Abramson Cancer Center at Penn Medicine
Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma
Milton S. Hershey Medical Center
Irinotecan and Carboplatin as Upfront Window Therapy in Treating Patients With Newly Diagnosed Intermediate-Risk or High-Risk Rhabdomyosarcoma
Memorial Sloan Kettering Cancer Center
Phase II Trial of Ribociclib and Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS)
Fox Chase Cancer Center
LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas
M.D. Anderson Cancer Center
Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers
M.D. Anderson Cancer Center
Iscador® P (Mistletoe) Immunotherapy for Recurrent Resectable Osteogenic Sarcoma
Hackensack Meridian Health
SATURN-STS: Phase II Study of Neoadjuvant Atezolizumab With Doxorubicin, Concurrent Atezolizumab With Pre-operative Radiation Therapy and Adjuvant Atezolizumab in Patients With High-risk Surgically Resectable Extremity and Truncal Soft Tissue Sarcoma
M.D. Anderson Cancer Center
PEMIGIST
Dana-Farber Cancer Institute
Ph 2 Elacestrant in ER Positive Uterine Sarcomas
Dana-Farber Cancer Institute
Cryoablation Plus Camrelizumab for Advanced Soft Tissue Sarcoma
Sun Yat-sen University
SARCOME13
UNICANCER
Evaluating Efficacy of B7-H3-CAR T Cells Administered at the End of Upfront Map Chemotherapy in Patients With Newly Diagnosed High-Risk Osteosarcoma
St. Jude Children's Research Hospital
Doxorubicin Hydrochloride Liposome Combined With Irinotecan (AI Regimen) Versus VIT Regimen in the Treatment of Relapsed and Refractory Pediatric Rhabdomyosarcoma: a Prospective, Open-label, Randomized Controlled, Multicenter, Phase II Clinical Study
Sun Yat-sen University
A Single-arm, Open-label, Single-center Prospective Study of Fruquintinib Combined With Envafolimab in the Treatment of Advanced or Unresectable Locally Advanced Bone and Soft Tissue Sarcoma
Shanghai 6th People's Hospital
A Study of Pembrolizumab in People With Ultra-Rare Sarcomas
Memorial Sloan Kettering Cancer Center
Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma
Northwestern University
Hypofractionated Radiotherapy for Soft Tissue Sarcomas
University of Wisconsin, Madison
Testing the Addition of Cemiplimab to Palbociclib for the Treatment of Advanced Dedifferentiated Liposarcoma
Alliance for Clinical Trials in Oncology
Intratumoral Vusolimogene Oderparepvec (VO) in Combination With Pembrolizumab for Angiosarcoma
University of California, San Francisco
Comparison of the Effects of Needle Biopsy Tract Resection and Non-resection on Recurrence Rate in Patients With Primary Extremity Sarcoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial
Fred Hutchinson Cancer Center
I-SPY
QuantumLeap Healthcare Collaborative
SPiReL
Sunnybrook Health Sciences Centre
A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors
Memorial Sloan Kettering Cancer Center
TARSARC
Institut Bergonié
Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue Sarcoma
City of Hope Medical Center
The CATSINDO Trial - Clinical and Translational Study in Newly Diagnosed Osteosarcoma
Wake Forest University Health Sciences
ALBATROSS
Yonsei University
SAVE-GEJ
Peking University People's Hospital
Comparing Regorafenib Combined With Envafolimab to Physician's Choice in Patients With Metastatic Gastrointestinal Stromal Tumors Harboring KIT Exon 17 Mutations Refractory to Standard Treatment
Peking University Cancer Hospital & Institute
A Study of Pembrolizumab and Olaparib in People With Endometrial Cancer or Endometrial Carcinosarcoma
Memorial Sloan Kettering Cancer Center
Study on the Treatment of Double/Triple-hit DLBCL With Chidamide and Lisaftoclax in Combination With Pola-R-CHP
Ruijin Hospital
Methionine PET/CT Studies In Patients With Cancer
St. Jude Children's Research Hospital
Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy
St. Jude Children's Research Hospital
ATEZOGIST
Centre Leon Berard
Efficacy and Safety of Envafolimab Plus Doxorubicin and Ifosfamide for Advanced Soft Tissue Sarcoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
A Study of Epacadostat, an IDO1 Inhibitor, in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma
Memorial Sloan Kettering Cancer Center
AG-120 in People With IDH1 Mutant Chondrosarcoma
Memorial Sloan Kettering Cancer Center
A Study of Pembrolizumab Plus Local Chemotherapy Using Isolated Limb Infusion (ILI) for Patients With Sarcoma in the Arm or Leg
Memorial Sloan Kettering Cancer Center
CONGRATS
Institut Bergonié
TORNADO
Institut Bergonié
Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas
University of Colorado, Denver
Thermal Ablation and Spine Stereotactic Radiosurgery in Treating Patients With Spine Metastases at Risk for Compressing the Spinal Cord
M.D. Anderson Cancer Center
Atezolizumab and Cabozantinib for the Treatment of Adolescents and Young Adults With Recurrent or Metastatic Osteosarcoma, TACOS Study
M.D. Anderson Cancer Center
Phase 2 Trial of Zanzalintinib and Pembrolizumab in Select Subtypes of Advanced/Metastatic Soft-tissue Sarcoma
M.D. Anderson Cancer Center
DOSa
M.D. Anderson Cancer Center
ANTARES
Instituto do Cancer do Estado de São Paulo
A Study of XmAb23104 in People With Sarcoma
Memorial Sloan Kettering Cancer Center